Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

Clinical trial NCT07233252 · RECRUITING

Trial details

NCT number: NCT07233252
Sponsor: Tianjin Medical University Second Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Renal Pelvic Carcinoma Tislelizumab PD-1 Inhibitor Kidney-sparing Nab-paclitaxel

Start date: 2025-11-25
Primary completion: 2026-12-30
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.